Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?

E-ISSN： 2212-3873|8|4|301-307

ISSN： 1871-5303

Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.8, Iss.4, 2008-12, pp. : 301-307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD)

Current Drug Discovery Technologies, Vol. 4, Iss. 2, 2007-08 ,pp. : 133-140

Bentham Science Publishers

Access to resources Recommend Favorite

Redox Homeostasis and Epigenetics in Non-alcoholic Fatty Liver Disease (NAFLD)

Current Pharmaceutical Design, Vol. 19, Iss. 15, 2013-03 ,pp. : 2737-2746

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD

Current Pharmaceutical Design, Vol. 19, Iss. 29, 2013-01 ,pp. : 5177-5192

Bentham Science Publishers

Access to resources Recommend Favorite

Models for Non-Alcoholic Fatty Liver Disease: A Link with Vascular Risk

Current Pharmaceutical Design, Vol. 14, Iss. 4, 2008-02 ,pp. : 378-384

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro Niosi Marco Vecchio Blanco Camillo Del Loguercio Carmela

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite